




RealRate

PHARMACEUTICAL 2022

CinCor Pharma Inc.
Rank 148 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2022

CinCor Pharma Inc.
Rank 148 of 475

The relative strengths and weaknesses of CinCor Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CinCor Pharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 157% points. The greatest weakness of CinCor Pharma Inc. is the variable Revenues, reducing the Economic Capital Ratio by 50% points.

The company's Economic Capital Ratio, given in the ranking table, is -4.7%, being 272% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	141,107
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,549
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	7,859
Property and Equipment	0
Research and Development	21,514
Revenues	0
Selling, General and Administrative Expense	20,996

Output Variable	Value in 1000 USD
Assets	141,107
Liabilities	16,549
Expenses	42,510
Stockholders Equity	124,557
Net Income	-34,652
Comprehensive Net Income	-34,652
Economic Capital Ratio	-4.7%

